Thermo Fisher Scientific Inc. of Waltham, Mass., has acquired Phadia of Uppsala, Sweden, a provider of blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases. Phadia now is part of Thermo Fisher’s Specialty Diagnostics business. The company is expected to contribute $0.07 to Thermo Fisher’s 2011 full-year adjusted earnings per share, an increase of $0.01 over the original estimate. In addition, it is expected to add $190 million to the US company’s 2011 revenue results, about a 12% growth in revenue over 2010.